Allogene Therapeutics, Inc. ALLO

US Biotechnology

$0.92 ▼ -13.43% ($-0.14)

🧊 52W Low ⬇️ Below Yest. Low

Open $1.04

Prev Close $1.06

Day Range $0.89 – $1.04

52W Range $0.98 – $4.46

Market Cap $367.26M

Beta 0.85

EPS (TTM) $-0.49

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2018-10-11
Shares Out.	345,490,000
Website	allogene.com/ ↗
Phone	13026365400
Employees	152
Revenue	$4.6M
Gross Profit	$4.6M
Net Income	-$42.7M
Free Cash Flow	-$102.6M
Total Assets	$550.1M
Total Liabilities	$113.9M
Equity	$436.2M

About Allogene Therapeutics, Inc.

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Allogene Therapeutics, Inc. is a publicly traded company under the ticker symbol ALLO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.